169 related articles for article (PubMed ID: 11912382)
1. How well does the Partin nomogram predict pathological stage after radical prostatectomy in a community based population? Results of the cancer of the prostate strategic urological research endeavor.
Penson DF; Grossfeld GD; Li YP; Henning JM; Lubeck DP; Carroll PR
J Urol; 2002 Apr; 167(4):1653-7; discussion 1657-8. PubMed ID: 11912382
[TBL] [Abstract][Full Text] [Related]
2. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
[TBL] [Abstract][Full Text] [Related]
3. Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer.
Blute ML; Bergstralh EJ; Partin AW; Walsh PC; Kattan MW; Scardino PT; Montie JE; Pearson JD; Slezak JM; Zincke H
J Urol; 2000 Nov; 164(5):1591-5. PubMed ID: 11025711
[TBL] [Abstract][Full Text] [Related]
4. Validation of 2001 Partin tables in Turkey: a multicenter study.
Eskicorapci SY; Karabulut E; Türkeri L; Baltaci S; Cal C; Toktas G; Akpinar H; Ozer G; Sozen S; Tokuc R; Lekili M; Soylu A; Albayrak S; Sahin H; Alpar R; Ozen H
Eur Urol; 2005 Feb; 47(2):185-9. PubMed ID: 15661412
[TBL] [Abstract][Full Text] [Related]
5. Ability of 2 pretreatment risk assessment methods to predict prostate cancer recurrence after radical prostatectomy: data from CaPSURE.
Mitchell JA; Cooperberg MR; Elkin EP; Lubeck DP; Mehta SS; Kane CJ; Carroll PR
J Urol; 2005 Apr; 173(4):1126-31. PubMed ID: 15758720
[TBL] [Abstract][Full Text] [Related]
6. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer.
Cagiannos I; Karakiewicz P; Eastham JA; Ohori M; Rabbani F; Gerigk C; Reuter V; Graefen M; Hammerer PG; Erbersdobler A; Huland H; Kupelian P; Klein E; Quinn DI; Henshall SM; Grygiel JJ; Sutherland RL; Stricker PD; Morash CG; Scardino PT; Kattan MW
J Urol; 2003 Nov; 170(5):1798-803. PubMed ID: 14532779
[TBL] [Abstract][Full Text] [Related]
7. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy.
Graefen M; Haese A; Pichlmeier U; Hammerer PG; Noldus J; Butz K; Erbersdobler A; Henke RP; Michl U; Fernandez S; Huland H
J Urol; 2001 Mar; 165(3):857-63. PubMed ID: 11176486
[TBL] [Abstract][Full Text] [Related]
8. The use of neural networks and logistic regression analysis for predicting pathological stage in men undergoing radical prostatectomy: a population based study.
Borque A; Sanz G; Allepuz C; Plaza L; Gil P; Rioja LA
J Urol; 2001 Nov; 166(5):1672-8. PubMed ID: 11586200
[TBL] [Abstract][Full Text] [Related]
9. The newer the better? Comparison of the 1997 and 2001 partin tables for pathologic stage prediction of prostate cancer in China.
Gao X; Ren S; Lu X; Xu C; Sun Y
Urology; 2008 Nov; 72(5):1096-101. PubMed ID: 18822453
[TBL] [Abstract][Full Text] [Related]
10. The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer.
Kattan MW; Shariat SF; Andrews B; Zhu K; Canto E; Matsumoto K; Muramoto M; Scardino PT; Ohori M; Wheeler TM; Slawin KM
J Clin Oncol; 2003 Oct; 21(19):3573-9. PubMed ID: 12913106
[TBL] [Abstract][Full Text] [Related]
11. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
[TBL] [Abstract][Full Text] [Related]
12. Prediction of pathological stage in patients with clinical stage T1c prostate cancer: the new challenge.
Veltri RW; Miller MC; Mangold LA; O'Dowd GJ; Epstein JI; Partin AW
J Urol; 2002 Jul; 168(1):100-4. PubMed ID: 12050500
[TBL] [Abstract][Full Text] [Related]
13. Preoperative neural network using combined magnetic resonance imaging variables, prostate-specific antigen, and gleason score for predicting prostate cancer biochemical recurrence after radical prostatectomy.
Poulakis V; Witzsch U; de Vries R; Emmerlich V; Meves M; Altmannsberger HM; Becht E
Urology; 2004 Dec; 64(6):1165-70. PubMed ID: 15596191
[TBL] [Abstract][Full Text] [Related]
14. Validity of the CAPRA score to predict biochemical recurrence-free survival after radical prostatectomy. Results from a european multicenter survey of 1,296 patients.
May M; Knoll N; Siegsmund M; Fahlenkamp D; Vogler H; Hoschke B; Gralla O
J Urol; 2007 Nov; 178(5):1957-62; discussion 1962. PubMed ID: 17868719
[TBL] [Abstract][Full Text] [Related]
15. Development and split-sample validation of a nomogram predicting the probability of seminal vesicle invasion at radical prostatectomy.
Gallina A; Chun FK; Briganti A; Shariat SF; Montorsi F; Salonia A; Erbersdobler A; Rigatti P; Valiquette L; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2007 Jul; 52(1):98-105. PubMed ID: 17267098
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma.
Kattan MW; Stapleton AM; Wheeler TM; Scardino PT
Cancer; 1997 Feb; 79(3):528-37. PubMed ID: 9028364
[TBL] [Abstract][Full Text] [Related]
17. Transition zone cancers undermine the predictive accuracy of Partin table stage predictions.
Steuber T; Karakiewicz PI; Augustin H; Erbersdobler A; Lange I; Haese A; Chun KH; Walz J; Graefen M; Huland H
J Urol; 2005 Mar; 173(3):737-41. PubMed ID: 15711259
[TBL] [Abstract][Full Text] [Related]
18. Comparison of accuracy between the Partin tables of 1997 and 2001 to predict final pathological stage in clinically localized prostate cancer.
Augustin H; Eggert T; Wenske S; Karakiewicz PI; Palisaar J; Daghofer F; Huland H; Graefen M
J Urol; 2004 Jan; 171(1):177-81. PubMed ID: 14665871
[TBL] [Abstract][Full Text] [Related]
19. Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml.
Makarov DV; Humphreys EB; Mangold LA; Walsh PC; Partin AW; Epstein JI; Freedland SJ
J Urol; 2006 Aug; 176(2):554-8. PubMed ID: 16813888
[TBL] [Abstract][Full Text] [Related]
20. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
